PubMed

NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia.

O'Brien S, Berman E, Borghaei H, Deangelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Pinilla-Ibarz J, Radich JP, Shah Md NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M, Wetzler M.

J Natl Compr Canc Netw. 2009 Oct;7(9):984-1023. No abstract available. PMID: 19878641 [PubMed - in process]Related articles

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.

Donato NJ, Fang D, Sun H, Giannola D, Peterson LF, Talpaz M.

Biochem Pharmacol. 2009 Oct 27. [Epub ahead of print]PMID: 19874801 [PubMed - as supplied by publisher]Related articles

Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.

Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A, Campagnaro E, Brozo C, Braun T, Talpaz M, Kaminski MS.

J Clin Oncol. 2009 Oct 20;27(30):5015-22. Epub 2009 Sep 8.PMID: 19738129 [PubMed - in process]Related articles

Following the hedgehog to new cancer therapies.

Dlugosz AA, Talpaz M.

N Engl J Med. 2009 Sep 17;361(12):1202-5. Epub 2009 Sep 2. No abstract available. PMID: 19726764 [PubMed - indexed for MEDLINE]Related articles

Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.

Dorr DA, Burdon R, West DP, Lagman J, Georgopoulos C, Belknap SM, McKoy JM, Djulbegovic B, Edwards BJ, Weitzman SA, Boyle S, Tallman MS, Talpaz M, Sartor O, Bennett CL.

Clin Cancer Res. 2009 Jun 1;15(11):3850-5. Epub 2009 May 19.PMID: 19458059 [PubMed - indexed for MEDLINE]Related articles

Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors.

Bixby DL, Talpaz M.

Clin Lymphoma Myeloma. 2008 Mar;8 Suppl 3:S95-S106. Review.PMID: 19254887 [PubMed - indexed for MEDLINE]Related articles

The fine tuning of therapy for chronic myeloid leukemia and upcoming challenges.

Talpaz M.

Clin Lymphoma Myeloma. 2008 Mar;8 Suppl 3:S74. No abstract available. PMID: 19254883 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Brümmendorf TH, Michallet M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JM, Talpaz M.

Leukemia. 2008 Dec;22(12):2176-83. Epub 2008 Aug 28.PMID: 18754032 [PubMed - indexed for MEDLINE]Related articles

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.

J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. Epub 2008 Jun 24.PMID: 18577747 [PubMed - indexed for MEDLINE]Related articlesFree article

Getting to the stem of chronic myeloid leukaemia.

Savona M, Talpaz M.

Nat Rev Cancer. 2008 May;8(5):341-50. Review.PMID: 18385684 [PubMed - indexed for MEDLINE]Related articles

Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1(T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain.

Quintás-Cardama A, Gibbons DL, Kantarjian H, Talpaz M, Donato N, Cortes J.

Leukemia. 2008 Apr;22(4):885-8. Epub 2008 Feb 28. No abstract available. PMID: 18305550 [PubMed - indexed for MEDLINE]Related articles

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.

Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, Talpaz M, Donato NJ.

Blood. 2008 Apr 1;111(7):3821-9. Epub 2008 Jan 30.PMID: 18235045 [PubMed - indexed for MEDLINE]Related articlesFree article

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

Kujawski L, Talpaz M.

Leuk Lymphoma. 2007 Dec;48(12):2310-22. Review.PMID: 18067005 [PubMed - indexed for MEDLINE]Related articles

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.

Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M, Erba H, Shedden K, Wang S, Malek SN.

Blood. 2008 Feb 1;111(3):1584-93. Epub 2007 Oct 30.PMID: 17971485 [PubMed - indexed for MEDLINE]Related articlesFree article

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.

Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM.

Blood. 2008 Feb 1;111(3):1039-43. Epub 2007 Oct 11. Erratum in: Blood. 2008 Jul 15;112(2):452. Gambacorti, Carlo [corrected to Gambacorti-Passerini, Carlo]. PMID: 17932248 [PubMed - indexed for MEDLINE]Related articlesFree article

The role of interferon-alpha in the treatment of chronic myeloid leukemia.

Kujawski LA, Talpaz M.

Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):459-71. Epub 2007 Aug 20. Review.PMID: 17703986 [PubMed - indexed for MEDLINE]Related articles

Chronic myelogenous leukemia.

O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, Przepiorka D, Radich JP, Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, Wetzler M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2007 May;5(5):474-96. No abstract available. PMID: 17509252 [PubMed - indexed for MEDLINE]Related articles

Degrasyn activates proteasomal-dependent degradation of c-Myc.

Bartholomeusz G, Talpaz M, Bornmann W, Kong LY, Donato NJ.

Cancer Res. 2007 Apr 15;67(8):3912-8.PMID: 17440106 [PubMed - indexed for MEDLINE]Related articlesFree article

Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.

Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Rios MB, Shan J, Giles F, Cortes J.

Cancer. 2007 Apr 15;109(8):1556-60.PMID: 17342766 [PubMed - indexed for MEDLINE]Related articlesFree article

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M.

Blood. 2007 May 15;109(10):4143-50. Epub 2007 Jan 30.PMID: 17264298 [PubMed - indexed for MEDLINE]Related articlesFree article

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.

Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ.

Blood. 2007 Apr 15;109(8):3470-8. Epub 2007 Jan 3.PMID: 17202319 [PubMed - indexed for MEDLINE]Related articlesFree article

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.

Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J.

Ann Intern Med. 2006 Dec 19;145(12):913-23. Review.PMID: 17179059 [PubMed - indexed for MEDLINE]Related articlesFree article

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.

Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, Cortes J.

Blood. 2007 Jan 15;109(2):497-9. Epub 2006 Sep 21.PMID: 16990591 [PubMed - indexed for MEDLINE]Related articlesFree article

Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.

Kurzrock R, Talpaz M, Li L, Estrov Z.

Leuk Lymphoma. 2006 Aug;47(8):1651-64.PMID: 16966279 [PubMed - indexed for MEDLINE]Related articles

TRAIL-induced cleavage and inactivation of SPAK sensitizes cells to apoptosis.

Polek TC, Talpaz M, Spivak-Kroizman TR.

Biochem Biophys Res Commun. 2006 Oct 27;349(3):1016-24. Epub 2006 Aug 28.PMID: 16950202 [PubMed - indexed for MEDLINE]Related articles

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.

Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J.

Leukemia. 2006 Oct;20(10):1767-73. Epub 2006 Jul 20.PMID: 16855631 [PubMed - indexed for MEDLINE]Related articles

Chronic myeloid leukemia: changing the treatment paradigms.

Savona M, Talpaz M.

Oncology (Williston Park). 2006 Jun;20(7):707-11; discussion 712-4, 719, 724. Review.PMID: 16841795 [PubMed - indexed for MEDLINE]Related articles

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.

N Engl J Med. 2006 Jun 15;354(24):2531-41.PMID: 16775234 [PubMed - indexed for MEDLINE]Related articlesFree article

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.

Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J.

Blood. 2006 Sep 15;108(6):1835-40. Epub 2006 May 18.PMID: 16709931 [PubMed - indexed for MEDLINE]Related articlesFree article

The TNF receptor, RELT, binds SPAK and uses it to mediate p38 and JNK activation.

Polek TC, Talpaz M, Spivak-Kroizman T.

Biochem Biophys Res Commun. 2006 Apr 28;343(1):125-34. Epub 2006 Mar 2.PMID: 16530727 [PubMed - indexed for MEDLINE]Related articles

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.

Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM.

Cancer. 2006 Mar 15;106(6):1306-15.PMID: 16463391 [PubMed - indexed for MEDLINE]Related articlesFree article

Pregnancy among patients with chronic myeloid leukemia treated with imatinib.

Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J.

J Clin Oncol. 2006 Mar 1;24(7):1204-8. Epub 2006 Jan 30.PMID: 16446320 [PubMed - indexed for MEDLINE]Related articles

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.

Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J.

Cancer. 2006 Jan 15;106(2):346-52.PMID: 16342165 [PubMed - indexed for MEDLINE]Related articlesFree article

Chronic myelogenous leukemia.

O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, Przepiorka D, Radich JP, Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, Wetzler M.

J Natl Compr Canc Netw. 2005 Nov;3(6):732-55. No abstract available. PMID: 16316611 [PubMed - indexed for MEDLINE]Related articles

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.

Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH.

Blood. 2006 Mar 15;107(6):2501-6. Epub 2005 Nov 15.PMID: 16291594 [PubMed - indexed for MEDLINE]Related articlesFree article

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.

Johnson FM, Saigal B, Talpaz M, Donato NJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32.PMID: 16203784 [PubMed - indexed for MEDLINE]Related articlesFree article

Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.

Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM, Reuben JM.

Leukemia. 2005 Nov;19(11):1905-11.PMID: 16151467 [PubMed - indexed for MEDLINE]Related articles

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.

Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H.

Clin Cancer Res. 2005 Sep 1;11(17):6247-55.PMID: 16144928 [PubMed - indexed for MEDLINE]Related articlesFree article

The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.

Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, Shan J, Cortes J.

Leuk Lymphoma. 2005 Jul;46(7):993-7.PMID: 16019549 [PubMed - indexed for MEDLINE]Related articles

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.

Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderl S, Wierda W, Rios MB, Shan J, Cortes J.

Cancer. 2005 Aug 15;104(4):777-80.PMID: 15971197 [PubMed - indexed for MEDLINE]Related articlesFree article

Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.

Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z.

Br J Cancer. 2005 Jul 11;93(1):70-80.PMID: 15970928 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.

Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM.

J Clin Oncol. 2005 Jun 10;23(17):3948-56. Epub 2005 May 9.PMID: 15883410 [PubMed - indexed for MEDLINE]Related articles

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.

Clin Cancer Res. 2005 May 1;11(9):3425-32.PMID: 15867244 [PubMed - indexed for MEDLINE]Related articlesFree article

Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.

Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S.

Cancer. 2005 Jun 15;103(12):2551-7.PMID: 15861412 [PubMed - indexed for MEDLINE]Related articlesFree article

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.

Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J.

Cancer. 2005 May 15;103(10):2099-108.PMID: 15830345 [PubMed - indexed for MEDLINE]Related articlesFree article

Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.

Tefferi A, Dewald GW, Litzow ML, Cortes J, Mauro MJ, Talpaz M, Kantarjian HM.

Mayo Clin Proc. 2005 Mar;80(3):390-402. Review.PMID: 15757021 [PubMed - indexed for MEDLINE]Related articlesFree article

Immune therapy of chronic myelogenous leukemia.

Gale RP, Horowitz MM, Talpaz M, Scheinberg DA, Molldrem J, Li Z, Baccarani M, Goldman JM, Tura S.

Leuk Res. 2005 May;29(5):583-6. No abstract available. PMID: 15755511 [PubMed - indexed for MEDLINE]Related articles

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.

Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J.

Blood. 2005 Mar 15;105(6):2281-6. Epub 2004 Nov 30.PMID: 15572595 [PubMed - indexed for MEDLINE]Related articlesFree article

Investigational strategies in chronic myelogenous leukemia.

Cortes JE, O'Brien SM, Giles F, Alvarez RH, Talpaz M, Kantarjian HM.

Hematol Oncol Clin North Am. 2004 Jun;18(3):619-39, ix. Review.PMID: 15271396 [PubMed - indexed for MEDLINE]Related articles

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.

Bueso-Ramos CE, Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, Medeiros LJ, Kantarjian H.

Cancer. 2004 Jul 15;101(2):332-6.PMID: 15241831 [PubMed - indexed for MEDLINE]Related articlesFree article